David Page, M.D., is passionate about improving cure rates and quality of life for women with breast cancer. A contributor to some of the first immunotherapy clinical trials in breast cancer, Dr. Page leads clinical trials to improve outcomes in breast cancer and develop alternative, more successful treatments to chemotherapy.
"My research focus is on using newer treatments that destroy cancer by empowering a woman's natural immune defenses," says Dr. Page. "These treatments, called immunotherapies, can be helpful in both newly-diagnosed breast cancer and in metastatic breast cancer." Dr. Page is leading two innovative immunotherapy clinical trials for patients with early-stage and metastatic breast cancer. In the first study, he is investigating whether a new immunotherapy, known as IRX-2, may improve outcomes in early-stage breast cancer while using less chemotherapy.